Ruxolitinib Achieves Disease Control in Mild to Moderate Atopic Dermatitis
Investigators evaluated atopic dermatitis control achieved with ruxolitinib cream as well as physician satisfaction with monotherapy and combination therapy outcomes.
Investigators evaluated atopic dermatitis control achieved with ruxolitinib cream as well as physician satisfaction with monotherapy and combination therapy outcomes.
Discovery of higher GSDMB expression in children with a genetic defect linked to asthma explains why they commonly experience viral infections and face an elevated…
“A blog about allergy, asthma & immunology”
The Department of Immunobiology at Yale School of Medicine is a multidisciplinary group of 30 faculty and more than 200 scientists-in-training and staff
This website uses cookies to ensure you get the best experience on our
Luminex Licensed Technology: Diasorin provides innovative xMAP® Technology solutions for fast, reliable answers in research, impacting daily patient health outcomes.
The report ‘is a complete U-turn,’ according to one expert
Biologic modifiers targeting type 2 (T2) airway inflammation are effective in reducing asthma exacerbation. However, real-world and comparative effectiveness studies remain limited.
The Kyowa Kirin Group is a Japanese pharma group that develops innovative specialty drugs, to raise the health and well-being of people around the world.…
Take Advantage of Cytek Biosciences full spectrum flow cytometry systems, offering many advantages over conventional flow cytometers.
CDI Labs is the autoantibody, autoantibodies seromics and proteomics company and creators of HuProt that seek to understand the impacts of the serome on human…